The Continuing Saga of Tissue Inhibitor of Metalloproteinase 2
The American Journal of Pathology · 2023-10 · 193 (10) · 1336-1352
DOI: 10.1016/j.ajpath.2023.08.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The American Journal of Pathology, 2023-10. Verfasst von William G Stetler-Stevenson. Beteiligte Einrichtung: Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address…. Hauptthemen laut MEDLINE: Tissue Inhibitor of Metalloproteinase-2, Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: sstevenw@mail.nih.gov.
Förderung
- Intramural NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Stetler-Stevenson, W. G. (2023). The Continuing Saga of Tissue Inhibitor of Metalloproteinase 2. The American Journal of Pathology, 193(10), 1336-1352. https://doi.org/10.1016/j.ajpath.2023.08.001
Vancouver
Stetler-Stevenson WG. The Continuing Saga of Tissue Inhibitor of Metalloproteinase 2. The American Journal of Pathology. 2023;193(10):1336-1352. doi:10.1016/j.ajpath.2023.08.001
BibTeX
@article{StetlerStevenson2023,
author = {Stetler-Stevenson, William G},
title = {The Continuing Saga of Tissue Inhibitor of Metalloproteinase 2},
journal = {The American Journal of Pathology},
year = {2023},
volume = {193},
number = {10},
pages = {1336--1352},
doi = {10.1016/j.ajpath.2023.08.001}
}
EUVIMED